Dr. Reddy's Laboratories Limited
RDYNYSEHealthcare● Active
$13.23
$-0.02(-0.11%)
Market Cap$11.0B
P/E Ratio—
52W High$16.17
52W Low$12.19
Dr. Reddy's Laboratories Limited (RDY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RDY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$0.06
Est. $0.09 · -33.3%
Revenue
$0.79B
Est. $0.89B · -11.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RDY reports quarterly as a NYSE-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.06
Rev. $0.47B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.06
Rev. Est.$0.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 22, 2026 | $0.10 | — | — | — | $0.83B | — |
| ▼ Q2 FY2026 | May 11, 2026 | $0.09 | $0.06 | -33.3% | $0.79B | $0.89B | -11.4% |
| — Q1 FY2026 | Jan 20, 2026 | $0.16 | $0.16 | +0.0% | $0.95B | $0.93B | +2.6% |
| ▼ Q4 FY2025 | Oct 24, 2025 | $0.19 | $0.19 | -1.4% | $0.99B | $0.94B | +5.0% |
| ▼ Q3 FY2025 | Jul 23, 2025 | $0.21 | $0.20 | -6.7% | $1.00B | $1.02B | -2.2% |
| ▲ Q2 FY2025 | May 9, 2025 | $0.21 | $0.22 | +4.0% | $0.99B | $0.99B | +0.8% |
| ◌ Q1 FY2025 | Jan 29, 2025 | $0.19 | — | — | — | $0.98B | — |
| ▼ Q4 FY2024 | Nov 5, 2024 | $0.21 | $0.04 | -80.6% | $0.95B | $0.91B | +5.0% |
Q3 FY2026
Jul 22, 2026
EPS Actual
—
EPS Est.
$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
$0.06
EPS Est.
$0.09
EPS Surpr.
-33.3%
Revenue
$0.79B
Q1 FY2026
Jan 20, 2026
EPS Actual
$0.16
EPS Est.
$0.16
EPS Surpr.
+0.0%
Revenue
$0.95B
Q4 FY2025
Oct 24, 2025Miss
EPS Actual
$0.19
EPS Est.
$0.19
EPS Surpr.
-1.4%
Revenue
$0.99B
Q3 FY2025
Jul 23, 2025Miss
EPS Actual
$0.20
EPS Est.
$0.21
EPS Surpr.
-6.7%
Revenue
$1.00B
Q2 FY2025
May 9, 2025Beat
EPS Actual
$0.22
EPS Est.
$0.21
EPS Surpr.
+4.0%
Revenue
$0.99B
Q1 FY2025
Jan 29, 2025
EPS Actual
—
EPS Est.
$0.19
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
$0.04
EPS Est.
$0.21
EPS Surpr.
-80.6%
Revenue
$0.95B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $13.11 | $13.11 | $13.11 | 1 |
| Q4 FY2026 | $12.74 | $12.74 | $12.74 | 1 |
| Q3 FY2026 | $11.04 | $11.04 | $11.04 | 1 |
| Q2 FY2026 | $9.33 | $9.33 | $9.33 | 1 |
| Q1 FY2026 | $11.07 | $11.07 | $11.07 | 1 |
| Q4 FY2025 | $13.81 | $13.81 | $13.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $86.7B | $86.7B | $86.7B | 1 |
| Q4 FY2026 | $85.3B | $85.3B | $85.3B | 1 |
| Q3 FY2026 | $82.3B | $82.3B | $82.3B | 1 |
| Q2 FY2026 | $77.2B | $77.2B | $77.2B | 1 |
| Q1 FY2026 | $82.4B | $82.4B | $82.4B | 11 |
| Q4 FY2025 | $83.3B | $83.3B | $83.3B | 12 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -33.3% | $13.23 | $13.14 | -0.68% |
| ▲ Q1 FY2026 | Jan 20, 2026 | +0.0% | $12.92 | $12.94 | +0.15% |
| ▼ Q4 FY2025 | Oct 24, 2025 | -1.4% | $14.62 | $14.58 | -0.27% |
| ▼ Q3 FY2025 | Jul 23, 2025 | -6.7% | $14.41 | $14.60 | +1.32% |
| ▲ Q2 FY2025 | May 9, 2025 | +4.0% | $13.18 | $13.40 | +1.67% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -80.6% | $14.80 | $14.61 | -1.28% |
| ▲ Q3 FY2024 | Jul 27, 2024 | +4.0% | $16.24 | $16.40 | +0.99% |
| ▼ Q2 FY2024 | May 8, 2024 | -18.6% | $14.27 | $14.30 | +0.21% |
Q2 FY2026-0.68%
Report Date
May 11, 2026
EPS Beat/Miss
-33.3%
Price Before
$13.23
Price After
$13.14
Q1 FY2026+0.15%
Report Date
Jan 20, 2026
EPS Beat/Miss
+0.0%
Price Before
$12.92
Price After
$12.94
Q4 FY2025-0.27%
Report Date
Oct 24, 2025
EPS Beat/Miss
-1.4%
Price Before
$14.62
Price After
$14.58
Q3 FY2025+1.32%
Report Date
Jul 23, 2025
EPS Beat/Miss
-6.7%
Price Before
$14.41
Price After
$14.60
Q2 FY2025+1.67%
Report Date
May 9, 2025
EPS Beat/Miss
+4.0%
Price Before
$13.18
Price After
$13.40
Q4 FY2024-1.28%
Report Date
Nov 5, 2024
EPS Beat/Miss
-80.6%
Price Before
$14.80
Price After
$14.61
Q3 FY2024+0.99%
Report Date
Jul 27, 2024
EPS Beat/Miss
+4.0%
Price Before
$16.24
Price After
$16.40
Q2 FY2024+0.21%
Report Date
May 8, 2024
EPS Beat/Miss
-18.6%
Price Before
$14.27
Price After
$14.30
Avg Beat Reaction+0.94%
Avg Miss Reaction-0.14%
Beat Rate3 / 8 quarters
Largest Move+1.67% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RDY ends December
Dr. Reddy's Laboratories Limited (RDY) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $0.06 — missing the analyst consensus of $0.09 by -33.3%. The next RDY earnings date is expected around September 1, 2026.
Each quarter, investors track RDY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RDY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RDY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RDY earnings · 5 questionsDr. Reddy's Laboratories Limited's next earnings report is expected around September 1, 2026. RDY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RDY historically reports after market close (AMC).
RDY earnings datewhen is RDY earningsRDY next earnings datewhen does RDY report earningsRDY earnings calendar
▸ Source: FMP · Dr. Reddy's Laboratories Limited SEC filings · US GAAP · Dr. Reddy's Laboratories Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026